Standardizing Nomenclatures in Radiation Oncology

The Report of AAPM Task Group 263

January 2018

DISCLAIMER: This publication is based on sources and information believed to be reliable, but the AAPM, the authors, and the editors disclaim any warranty or liability based on or relating to the contents of this publication.

The AAPM does not endorse any products, manufacturers, or suppliers. Nothing in this publication should be interpreted as implying such endorsement.
Standardizing Nomenclatures
in Radiation Oncology

The Report of AAPM Task Group 263

Charles S. Mayo, Chair
University of Michigan,
Ann Arbor, Michigan

Jean M. Moran, Vice Chair
University of Michigan,
Ann Arbor, Michigan

Walter Bosch
Washington University, St. Louis, Missouri

Ying Xiao
University of Pennsylvania,
Philadelphia, Pennsylvania

Todd McNutt
Johns Hopkins University,
Baltimore, Maryland

Richard Popple
University of Alabama at Birmingham,
Birmingham, Alabama

Jeff Michalski
Washington University, St. Louis, Missouri

Mary Feng
University of California San Francisco,
San Francisco, California

Lawrence B. Marks
University of North Carolina,
Chapel Hill, North Carolina

Clifton D. Fuller
MD Anderson Cancer Center,
Houston, Texas

Ellen Yorke
Memorial Sloan Kettering Cancer Center,
New York, New York

Jatinder Palta
Virginia Commonwealth University,
Richmond, Virginia

Peter E. Gabriel
University of Pennsylvania,
Philadelphia, Pennsylvania

Andrea Molineu
MD Anderson Cancer Center,
Houston, Texas

Martha M. Matuszak
University of Michigan,
Ann Arbor, Michigan

Elizabeth Covington
Birmingham, Alabama

Kathryn Masi
Karmanos Cancer Center, Detroit, Michigan

Susan L. Richardson
Swedish Medical Center,
Seattle, Washington

Timothy Ritter
Hunter Holmes McGuire VA Medical Center, Richmond, Virginia

Tomasz Morgas
Varian Medical Systems,
Palo Alto, California

Stella Flampouri
University of Florida, Jacksonville, Florida

Lakshmi Santanam
Washington University, St. Louis, Missouri

Joseph A. Moore
Johns Hopkins University,
Baltimore, Maryland

Thomas G. Purdie
The Princess Margaret Cancer Center,
Toronto, ON, Canada

Robert Miller
Mayo Clinic, Jacksonville, Florida

Coen Hurkmans
Catharina Hospital, Department of Radiation Oncology, Eindhoven, The Netherlands

Judy Adams
Massachusetts General Hospital,
Boston, Massachusetts

Qing-Rong Jackie Wu
Duke University, Durham, North Carolina

Colleen J. Fox
Dartmouth-Hitchcock Medical Center,
Lebanon, New Hampshire

Ramon Alfredo Siochi
West Virginia University,
Morgantown, West Virginia

Norman L. Brown
Baptist Medical Center, Jacksonville, Florida

Wilko Verbakel
VU University Medical Center,
Amsterdam, Netherlands

Yves Archambault
Varian Medical Systems,
Palo Alto, California

Steven J. Chmura
University of Chicago, Chicago, Illinois

Don G. Eagle
Northwest Medical Physics Center,
Lynnwood, Washington

Thomas J. Fitzgerald
University of Massachusetts,
Worcester, Massachusetts

Andre L. Dekker
Department of Radiation Oncology
(MAASTRO), GROW School for Oncology
and Developmental Biology, Maastricht
University Medical Centre++, Maastricht,
The Netherlands

Theodore Hong
Massachusetts General Hospital,
Boston, Massachusetts

Rishabh Kapoor
Virginia Commonwealth University,
Richmond, Virginia

Beth Lansing
Elekta Corporation, St. Louis, Missouri

Shruti Jolly
University of Michigan,
Ann Arbor, Michigan

Mary E. Napolitano
Consultant, Suwanee, Georgia

James Percy
Elekta Corporation, St. Louis, Missouri

Mark S. Rose
Sun Nuclear, Melbourne, Florida

Salim Siddiqui
Henry Ford Health System,
Detroit, Michigan

Christof Schadt
Brain Lab, Chicago, Illinois

William E. Simon
Sun Nuclear Corporation,
Melbourne, Florida

William L. Straube
Washington University, St. Louis, Missouri

Sara T. St. James
University of Washington,
Seattle, Washington

Kenneth Ulin
University of Massachusetts,
Worcester, Massachusetts

Sue S. Yom
University of California San Francisco,
San Francisco, California

Torunn Yock
Massachusetts General Hospital,
Boston, Massachusetts
DISCLAIMER: This publication is based on sources and information believed to be reliable, but the AAPM, the authors, and the publisher disclaim any warranty or liability based on or relating to the contents of this publication.

The AAPM does not endorse any products, manufacturers, or suppliers. Nothing in this publication should be interpreted as implying such endorsement.

ISBN: 978-1-936366-61-3
ISSN: 0271-7344

© 2018 by American Association of Physicians in Medicine

All rights reserved

Published by
American Association of Physicians in Medicine
1631 Prince Street
Alexandria, VA 22314
Contents

1. Introduction ................................................................. 6

2. Background ................................................................. 6
   2.1 Data Pooling ............................................................ 6
   2.2 Facilitating Communication During Routine Care ................. 7
   2.3 Automatic Data Extraction and Exchange ....................... 7
   2.4 Challenges Despite Some Progress ................................ 7

3. Task Group Initiation and Membership ................................ 8

   4.1 Dose and Volume Units .............................................. 9
   4.2 Non-Target Structure Nomenclature ................................ 9
   4.3 Nomenclature for Target Structures ............................. 10
   4.4 Derived and Planning Structures ................................. 10
   4.5 Vendor and DICOM Limitations ........................................ 11

5. Related Standards ......................................................... 12
   5.1 Foundational Model of Anatomy ................................ 12
   5.2 SNOMED CT ............................................................ 13
   5.3 DICOM ................................................................. 14
      5.3.1 DICOM Structure Interpreted Types ....................... 14
      5.3.2 DICOM Dose and Imaging Information Specification ..... 14
      5.3.3 Other Considerations for DICOM Dose and Imaging Specification ........................................ 15

6. Color Specification ....................................................... 16

7. Recommendations for Non-Target Structure Nomenclature ........ 16
   7.1 Approach .............................................................. 16
   7.2 Guiding Principles for Non-Target Nomenclature ................. 17
   7.3 Structure Nomenclature List ........................................ 19

8. Recommendations for Target Structure Nomenclature .............. 20
   8.1 Approach .............................................................. 20
   8.2 Guiding Principles for Target Nomenclature ...................... 21

9. Recommendations for Dose Volume Histogram Metrics ............ 23
   9.1 Approach .............................................................. 23
   9.2 Guidelines for DVH Curve Metrics .................................. 24

10. Recommendations for Distinguishing Metrics of Segmented vs
    Non-Segmented Target Structures .................................... 25

11. Recommendations to Vendors ........................................ 26

12. Nomenclature Pilot Study Design and Results .................... 30
   12.1 Pilot Study Design .................................................. 30
   12.2 Pilot Study Results ................................................ 30

13. Recommendations for Implementation ................................ 32

14. Recommendations for Clinical Trial Study Groups ................ 33

15. Recommendations for Working Group to Succeed Task Group .... 33

16. Summary of Key Take-Home Points .................................. 34

17. Acknowledgments ....................................................... 35

18. References .............................................................. 36
1. Introduction

The radiation oncology community can benefit from standardized nomenclatures applied to targets, normal tissue structures, and treatment planning concepts and metrics. Such conformity enhances safety and quality efforts within and between clinics for routine ongoing practice, and it enables data pooling for outcomes research, registries, and clinical trials. Standardization is a vital precursor to the development of scalable uses of scripting for quality assurance and treatment plan evaluation. Increased clarity and consistency through standardizing nomenclatures in these areas would provide broad benefits.

The charge of AAPM Task Group 263 is to provide nomenclature guidelines in radiation oncology for use in clinical trials, data-pooling initiatives, population-based studies, and routine clinical care by standardizing:

1. structure names across image processing and treatment planning system platforms;
2. nomenclature for dosimetric data (e.g., dose/volume histogram [DVH]-based metrics);
3. templates for clinical trial groups and users of an initial subset of software platforms to facilitate adoption of the standards; and
4. formalism for nomenclature schema which can accommodate the addition of other structures defined in the future.

2. Background

Much has been learned from the groups which have instituted standardized nomenclatures for structures and for DVH metrics to facilitate development of outcomes databases, automated analysis of DVH metrics, and inter-institutional data exchanges. While some standards for structures have been published, no single standard has been generally endorsed with multi-institutional and multi-vendor consensus. In addition, the standards that exist have generally not been comprehensive (e.g., providing subsets but not the full set of dose/volume metrics, vendor system constraints, generalizability, nor radiobiological factors).

2.1 Data Pooling

A key vision of the QUANTEC collaboration was promotion of a culture of data pooling among institutions to promote dose/volume/outcome research. The QUANTEC papers highlighted the importance of standardizing what data elements are collected and how they are reported to reduce barriers to development of shared wisdom through efficient use of combined data sets. At approximately the same time, the value of standardizations to improve quality assurance in clinical trials was highlighted. The Imaging and Radiation Oncology Core (IROC) group was established as part of the National Clinical Trials Network (NCTN) to carry out clinical trial quality assurance. The National Cancer Institute (NCI) reorganized the clinical trials system in early 2014 by forming the NCTN to better promote large, multi-institutional trials. To promote participation of a broad range of institutions in clinical trials, it is critical to provide physicists, physicians, and other personnel with tools and methods within their clinics to efficiently support submission of high-quality data to the clinical trial quality assurance (QA) centers. The movement of professional organizations toward expectations for data sharing and similar requirements for publication in some journals is growing stronger. Standardization is a crucial component in making shared data more accessible and usable to benefit patient care. AAPM Task Group 113 recommends standardizing nomenclature because it facilitates interaction between all participants in clinical trials, ranging from the personnel at the institution performing...
the planning and quality steps to the quality assurance centers and principal investigators who are responsible for reviewing submitted data.\textsuperscript{13}

\subsection*{2.2 Facilitating Communication During Routine Care}

As part of routine patient care, establishing a common nomenclature used by clinics and vendors enables an improved exchange of data for patients who visit multiple clinics.\textsuperscript{8} A common nomenclature also improves safety by minimizing variability and ambiguity. The nomenclature is also an important enabling factor for construction of software solutions that can automate portions of the plan quality control process and improve safety.\textsuperscript{3,14–16}

The National Patient Safety Agency and the Radiation Oncology Safety Information System (ROSIS) published adverse events (or incidents) in radiation therapy and reported that they were primarily due to wrong “communication of intent”.\textsuperscript{17,18} Similarly, the Radiation Oncology–Incident Learning System, sponsored by ASTRO and AAPM, has identified miscommunication of the radiation therapy prescription as a problem\textsuperscript{19}. As a result, improved communication in radiation therapy is a cornerstone of ASTRO’s white paper on standardizing dose prescriptions.\textsuperscript{20} These reports document the deleterious effects of inaccurate or incomplete communication.

Standardizing structure names is one of the key factors that needs attention. Integration of standardized structure names into the Digital Imaging and Communications in Medicine (DICOM) standard or the Integrating the Healthcare Enterprise in Radiation Oncology (IHE-RO) Integration Profiles can pave the way toward safe transfer of information and, in turn, help automate QA processes. For example, conformance of target names or verification of laterality designations could be built into automated QA checks.

\subsection*{2.3 Automatic Data Extraction and Exchange}

The use of standard nomenclature is an essential enabling step for construction and use of tools to automatically extract pertinent data from the medical records in support of clinical trials, data-pooling initiatives, and clinical practice improvement. Even if natural language processing (NLP) of free text fields may be a desirable vision for the future, a simple adoption of standards is the best choice for implementation in today’s environment. Use of a common nomenclature provides a foundation for development of common software tools to automate data extraction and analysis, data submission, exchange, and QA.

\subsection*{2.4 Challenges Despite Some Progress}

Nomenclatures and ontologies relevant to structures have been developed that facilitate consistencies in communication, enhancing safety and quality for some clinical practices\textsuperscript{2,3} and trials.\textsuperscript{1} However, several barriers prevent more general usage of the already-proposed systems, including:

- Vendor-based challenges
  - Inter-vendor variation on constraints for character strings used for structures, including length, special characters, and capitalization.
  - Developing software using formats that are compatible with internal and common web-based data transmission formats (e.g., XML, JSON and DICOM, databases, and the upcoming HL7 FHIR standard) and with regular expression software tools.

- Multi-institutional-based challenges
  - Lack of a clear multi-institutional oversight group to take charge of coordinating the standards.
  - Lack of guidelines that extend across multiple languages, even when the specific names cannot.
Lack of a common language standard for definition of nomenclatures.

Challenges with mapping previously utilized nomenclature to new standards.

Lack of translation tables for mapping definitions from one language to another.

Lack of participation in multi-institutional clinical trials.

- Single institutional-based challenges
  - Incompatibility with requirements of data governance standards used at some institutions.
  - Cost and effort to implement a new nomenclature.
  - Compatibility with differing treatment modalities: external beam photons, electrons, particle therapy, and brachytherapy.
  - Consistent use of standards by the range of staffing groups interacting with patient charts (e.g., physicians, physicists, therapists, and dosimetrists).

- Clinical staff challenges
  - Inconsistent approaches to consider/define laterality and other structure qualifiers.
  - Lack of detailed and site-specific guidelines for the definition of target structures to enable automated computer algorithms to extract relevant information.
  - Lack of a schema that allows inclusion of anatomic structures and other structures (e.g., buffers on organs-at-risk (OARs) such as cord + 5 mm, body-PTV) that are utilized for dose evaluation in clinical protocols.
  - Lack of clear guidelines for clarifying or incorporating new elements of a standard nomenclature.

3. Task Group Initiation and Membership

The American Association of Physicists in Medicine (AAPM) formed a task group (TG-263) to develop a consensus position on nomenclature. This multi-institutional and multi-vendor collaboration involves physicists, physicians, and others engaged in electronic transfer of information. The membership of this group is larger than typical for an AAPM task group because the audience is broad. Wide representation, including members of the NRG Oncology (NRG) and other NCTN groups, was important so that the recommendations would encompass a comprehensive set of viewpoints and enable wide adoption throughout the radiation oncology community.

The Task Group 263 is composed of a diverse international group of 57 stakeholders: hospital-based physicists (33) and physicians (15), vendor representatives (8), and dosimetrists (1). The task group includes AAPM (39) and American Society for Radiation Oncology (ASTRO) (41) members, large academic centers (16), community clinics (6), vendors (5), and leaders from NRG (3), IHE-RO (2), and the DICOM Working Group 7 (2). Many TG members were also members of clinical trial groups—including NRG, Radiation Therapy Oncology Group (RTOG), Children’s Oncology Group (COG), and IROC—and had been involved in creating standardization templates within those groups. The group expanded from the original 20 members as deliberations became more clearly defined and an enhanced perspective on particular topics was needed (e.g., physician input on target naming, vendor input on technical constraints).
4. Initial Evaluation of Current Nomenclature Practices

The group began its work with an initial assessment of published nomenclatures, unpublished nomenclatures used in commercially available systems, and unpublished nomenclatures at major academic centers. A survey of the initial 20 task group members collected information on nomenclature standards at their respective institutions for target and non-target structures, dose volume histogram metrics, dose (Gy vs cGy) and volume units (mL vs cc) used in naming, and vendor constraints on character strings. Members were also surveyed on conventions for how overlapping structures were contoured for evaluation of DVH metrics.

The objective of this survey was not to define and embrace the most commonly used approaches. Instead, the objective was to categorize commonalities and variations in approaches at multiple institutions and to provide examples to discuss later during development of guiding principles and specific recommendations by the task group.

4.1 Dose and Volume Units

In the evaluation, the most commonly used unit to specify dose to target structures was cGy. For example, when dose was incorporated into naming a PTV structure which was prescribed to receive 5040 cGy, PTV5040 was more commonly selected than PTV50.4. Alternatively, the units used to specify doses to normal tissues in DVH nomenclatures were most commonly Gy, (e.g., V20Gy[%] instead of V2000cGy[%].) The most frequent standard unit for reporting volume was cc rather than mL or ml.

4.2 Non-Target Structure Nomenclature

For normal structures, groups reported having nomenclatures in place for some (16 of 20) or most (12 of 20) of their disease sites. The number of structures defined by these groups ranged from 21 to 311, with only 5 reporting more than 100 items in their nomenclature. Several groups indicated referencing, but not strictly following, the nomenclature published by Santanam, et al.2 Note that Yu, et al. recently published the nomenclatures used by the NRG as part of the TRIAD system.1 Two of the nomenclatures linked specific structures to the Foundational Model of Anatomy (FMA).21 Respondents indicated that laterality as a prefix was used twice as often as a suffix on the root name for the structure. Selection of prefix vs suffix was generally based on prioritizing sorting to group structure types (e.g., all optic nerve structures together, suffix) or guaranteed visibility of laterality (prefix) when the number of characters in the display was small.

Most nomenclatures attempted to follow a uniform pattern, and differences are illustrated with a few examples in Table 1.

Table 1. Variations in standardized nomenclatures reported for non-target structures by 16 institutions. The number in () indicates the number of respondents using the same value if > 1.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Number of Institutions</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left Optic Nerve</td>
<td>12</td>
<td>Lt Optic Nerve, OPTICN_L, OPTNRV_L, optic_nrv_l, l_optic_nerve, OPTIC_NRV_L, OpticNerve_L, LOPTIC, OpticNerve_L (3), Lef Optic Nerve, ON_L</td>
</tr>
<tr>
<td>Left Lung</td>
<td>12</td>
<td>Lt Lung, Lung_L(4), LUNG_L(3), lung_l, L_lung, LLUNG, L Lung</td>
</tr>
<tr>
<td>Both Lungs</td>
<td>12</td>
<td>Lungs(2), LUNGs, LUNG_TOTAL, lung_total, combined_lung, LUNG, LUNGs(2), Lung.BilatLung, Lung_Both</td>
</tr>
<tr>
<td>8th Cranial Nerve</td>
<td>7</td>
<td>CN_VIII(5), cn_viii(2), CN8, CN_8</td>
</tr>
<tr>
<td>Right External Iliac Artery</td>
<td>2</td>
<td>A_ILIAC_E_R, a_iliac_e_r</td>
</tr>
</tbody>
</table>
Convergence was greatest for simple structures requiring few characters (e.g., heart or HEART). Variations increased as the number of characters required to represent the structure increased; technical limitations on character strings displayed by the different vendors, and local preferences for capitalizations and separation of elements by spaces, underscores, or combinations of upper and lower case characters, were the main reasons for variations in nomenclature. Most groups had created nomenclatures for common structures (left lung) but had not developed a consistent naming strategy for a more comprehensive list of structures (right external iliac artery).

### 4.3 Nomenclature for Target Structures

Target structures showed wider variation in nomenclature approaches than non-target structures. Various combinations of prefixes and suffixes for ICRU-defined targets (GTV, CTV, ITV, PTV) as well as tumor bed volumes (TBV), internal gross target volumes (IGTV), and internal clinical target volumes (ICTV) were used to define the target location, target number, structure type, dose delivered, revision number, identity of person contouring, etc. Variations in capitalization and element separations were similar to normal structures. Thirteen institutions reported standardized nomenclatures for targets, and examples of different nomenclatures are listed in Table 2.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Number of Institutions</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTV</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Dose information only</td>
<td>5</td>
<td>PTV5040</td>
</tr>
<tr>
<td>Dose + primary or nodal volumes</td>
<td>2</td>
<td>PTVp_5040</td>
</tr>
<tr>
<td>Enumerations of target volumes (PTV1)</td>
<td>6</td>
<td>PTVp1_5040</td>
</tr>
<tr>
<td>Only enumerations of target volumes</td>
<td>2</td>
<td>PTV1</td>
</tr>
<tr>
<td>Relative dose indicators</td>
<td>2</td>
<td>ptv_high; ptv_intermediate; ptv_low</td>
</tr>
<tr>
<td>GTV</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Dose-based suffix</td>
<td>7</td>
<td>GTV5040, CTV_nodal_5040</td>
</tr>
<tr>
<td>Target-specifying suffixes</td>
<td>2</td>
<td>p.n.nodal, LNs, Lung</td>
</tr>
</tbody>
</table>

### 4.4 Derived and Planning Structures

Derivative structures are formed from target or non-target structures, typically using Boolean operations, e.g., intersection (x AND y), combination (x OR y), subtraction (x AND NOT y), and margins (x+1.0). Five institutions indicated that nomenclatures for derivative structures were used to define conditions for evaluating the dose distribution (e.g., OAR contour excluding PTV). Variations in several structures were common (e.g., body-ptv, PTV_EVAL, eval_PTV), but wide variation was noted for structures involving multiple concepts (e.g., NS_Brain-PTVs, optCTV-N2R5L_MRT1_ex-3600-v12).

Institutions indicated that structures were frequently created as a tool for dose optimization as opposed to dose evaluation. For example, an optimization structure created from a copy of the PTV structure with a Boolean operation excluding critical OAR structures from it to reflect dose compromises in plan optimization is routinely created by multiple institutions. However, naming conventions for such structures varied among members (e.g., modPTV, opt PTV, PTV_OPT). Although clinical flow may improve with minimal constraints on naming of dose sculpting structures, members noted that these structures can present a safety issue if they are confused with the structures used for dose evaluation (e.g., PTV, PTVHot, PTVCold, Ring, DLA.) To minimize possible usage for the wrong
purpose, several institutions selected a single character (e.g., ‘z’ or ‘_’) that was uniformly applied as a prefix to those structures. This prefix ensured that in an alphabetical sort they appeared at the end or beginning of the list (e.g., PTV, zPTVHot, zPTVCold, zRing, zDLA). Selection of z as a prefix is suggested.

4.5 Vendor and DICOM Limitations

Standardized nomenclature must be used on the widest possible range of systems in radiation oncology. This broad application requires consideration not only of treatment planning systems and treatment management systems, but also formats used for transmission of data (e.g., XML, JSON, DICOM), and standard software methods (e.g., regular expression) used during automated computer extraction of data elements from character strings.

Examples of characters that are frequently incompatible with restrictions of software systems for naming structures are shown in Table 3. Some treatment planning systems do not allow or may not be configured to use periods, or may limit the number of periods in the name. Therefore, we wanted to limit the nomenclature to strictly alphanumeric characters with only a few specifically allowed characters (e.g., underscore, dash, caret, plus, equals, exclamation point) to be flexible across multiple platforms. Some commercially available systems do not allow capitalized characters. While the nomenclature does make use of capitalized characters for readability, the string IDs need to remain unique when converted to all upper or lower case to maximize utility on those restrictive systems. Vendor limits on the lengths of character strings for naming structures are a significant hurdle. While some commercially available systems may allow storage of very long character strings for names, their displays have more restrictive constraints. This results in display of a truncated version of the full name in key areas or reports for the treatment plan. This may limit users from applying important annotations at the end of the structure and instead require that the important annotations, such as laterality, be placed at the beginning of the structure name.

Table 3: Examples of compatible and incompatible special characters. Unicode values corresponding to the Universal Coded Character Set Standard UTF-8 hexadecimal values are listed.

<table>
<thead>
<tr>
<th>Compatible Characters</th>
<th>Incompatible Characters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Character</strong></td>
<td><strong>Unicode</strong></td>
</tr>
<tr>
<td>_</td>
<td>underscore U-005F</td>
</tr>
<tr>
<td>-</td>
<td>dash - minus U-002D</td>
</tr>
<tr>
<td>^</td>
<td>caret U-005E</td>
</tr>
<tr>
<td>+</td>
<td>plus sign U-002B</td>
</tr>
<tr>
<td>=</td>
<td>equals sign U-003D</td>
</tr>
<tr>
<td>!</td>
<td>exclamation point U+0021</td>
</tr>
<tr>
<td>~</td>
<td>tilde U-0073</td>
</tr>
<tr>
<td></td>
<td>pipe U+007C</td>
</tr>
<tr>
<td></td>
<td>asterisk U+002A</td>
</tr>
<tr>
<td>(</td>
<td>left parenthesis U+0028</td>
</tr>
<tr>
<td>&amp;</td>
<td>ampersand U+0026</td>
</tr>
<tr>
<td>$</td>
<td>dollar sign U+0024</td>
</tr>
</tbody>
</table>
5. Existing Standards

The task group investigated existing standardizations frequently discussed in the context of radiation oncology nomenclature. Among these are ontologies which provide a framework for defining concepts and interrelationships intended for use in machine learning applications. These are not sufficient for the needs of a clinical radiation oncology nomenclature since they do not accommodate many of the practical issues outlined in section 2.4. Better understanding of what these ontologies are assists in understanding how linkage of the nomenclature to the ontologies, where possible, improves interoperability and incorporation into the wider health care informatics community.

These and other standardized terminologies and ontologies relevant to the work of the task group can be accessed at the BioPortal website maintained by the National Center for Biomedical Ontology, at http://bioportal.bioontology.org/ontologies.

5.1 Foundational Model of Anatomy

The Foundational Model of Anatomy ontology (FMA) compiles knowledge of human anatomy and is open-source, owned and maintained by the Structural Informatics Group at the University of Washington, Seattle, WA. FMA defines anatomic structures and interrelationships necessary for a phenotypic representation of the human body. It provides extensive detail of structures; however, it has limitations for applicability as a nomenclature and comprehensive representation of radiation oncology-specific structures (e.g., Bowel_Bag, SpinalCord_PRV, ICRU-based target specifications). Each structure is associated with a unique numerical identification code, the FMAID. Figure 1 provides an example of

![Figure 1. Illustration of the Foundational Model of Anatomy Ontology applied to lung volumes. The focus of the ontology is defining concepts and relationships in a format consumable by programs used in machine learning. The ontology is widely used in informatics but omits some concepts used in routine clinical care and does not address practical clinical issues for target and non-target structures that are addressed by the task group recommendations. Where there are common structures, the task group nomenclature identifies the ID of the corresponding FMA structure.](image-url)
portions of the FMA class hierarchy related to the lungs (FMAIDs not shown). In the group’s recommendation for nomenclature, the FMA identification code (FMAID) which most closely matches each item is also specified. The FMA may be accessed on-line at the NIH BioPortal at http://bioportal.bio-ontology.org/ontologies/FMA or at the University of Washington (Seattle, WA) website at http://xiphoid.biostr.washington.edu/fma/index.html.

5.2 SNOMED CT

The Systematized Nomenclature of Medicine–Clinical Terms (SNOMED CT) is a standardized terminology owned and licensed by the International Health Terminology Standards Development Organization (London, UK). It provides a framework for defining health care concepts and interrelationships among them to improve utilization of information across electronic records. Linkages can be very complicated and go well beyond physical anatomy. However, like the FMA, concepts may be incomplete for the purposes of radiation oncology, and character strings for names are unable to meet constraints of commercially available systems. Figure 2 illustrates a sample of a SNOMED CT concept that relates to the lungs and lung cancer as a disease. Each concept is associated with a unique numerical code. In the task group’s recommendation for nomenclature, the SNOMED CT code (SCTID) which most closely matches each item is identified. A list of SNOMED CT browsers is available on-line at http://ihtsdo.org/fileadmin/user_upload/doc/browsers/browsers.html and at http://browser.ihtsdo.org.

Equivalent SNOMED CT codes are not supplied in the task group’s recommendations for nomenclature. However, equivalent SNOMED CT codes may be derived from thesauri that maintain mappings between terminologies. The U.S. National Library of Medicine (NLM) provides one such thesaurus. The Unified Medical Language System (UMLS) is available at https://www.nlm.nih.gov/research/umls/. Users may subscribe to the site at no cost to access a metathesaurus browser which links concepts among ontologies, including SNOMED CT and FMA. Users interested in ontologies

![](figure2.png)

**Figure 2.** Illustration of a SNOMED CT concepts applied to lung cancer. SNOMED CT encompasses health care concepts beyond the purely anatomic goals of FMA. SNOMED CT is widely referenced in healthcare informatics. It has similar limitations as FMA for direct use as a nomenclature.
for data sharing can find additional resources at UMLS, including the Logical Identifiers Names and Codes (LOINC) and an ontology for generic and branded drugs named RxNorm.

The SNOMED CT and FMA ontologies are important touchpoints for the nomenclature, but they do not currently meet the needs addressed by the nomenclature presented in this report. SNOMED CT and FMA ontologies do not meet the requirements for anatomic, non-anatomic, and target structure concepts and the necessary compatibility with vended systems to enable practical clinical use. The nomenclature defined by the task group identifies connections to FMA, where applicable. We recommend use of UMLS resources for establishing linkages between FMA and SNOMED CT concepts.

5.3 DICOM

DICOM is a key technology standard in radiation oncology that enables data transfer for both clinical and research efforts. The length of structure names that can be represented by the region of interest (ROI) Name (3006,0026) attribute in the DICOM RT Structure Set information object is 64 characters. The number of characters maintained and displayed by applications is generally much fewer. Practical character limitations are not in the DICOM standard itself, but rather in the implementation of the standard in clinical applications. The ability to track structure provenance and linkage to other concepts (e.g., prescription) using ROI Names is limited. While not yet generally implemented, code schemes and controlled terminology can be used in DICOM to identify and categorize structures. It should be mentioned that DICOM, unlike SNOMED CT and FMA, is not an ontology that tries to define, link, and enforce the semantics (meaning) of concepts, but is a mostly syntactic standard to transfer and store information in a consistent manner.

5.3.1 DICOM Structure Interpreted Types

DICOM-RT currently supports a well-defined ROI Interpreted Type (3006,00A4) attribute that adds granularity to ROI and point of interest (POI) for a given radiation treatment plan. These interpreted types can provide structured, standardized adjuvant information for a given ROI or POI that overcomes the shortfalls of free-text strings. An extensible set of Defined Terms for interpreted types is listed in Table 4.

In addition to the ROI Interpreted Type, the DICOM standard provides attributes that can be used to track the identity of the physician contouring (ROI Interpreter (3006,00A6)) and record the reference images used for contouring, such as MR over layered on CT and reference phase on 4DCT, and the image datasets used for contouring that were co-registered to each other (ROI Observation Label (3006,0085)). Coordinated support for these attributes by vendors could provide important extensions to an integrated nomenclature system.

5.3.2 DICOM Dose and Imaging Information Specification

For all evaluated ROIs, there is often a specific dose of relevance relating to the prescribed dose and fractionation. The purpose of the ROI interpreted type in DICOM is to identify the class of an ROI, which can help to provide contextual information for the dose field. The DICOM RT Prescription IOD (Information Object Definition; part of Supp. 147, in preparation) conveys the dosimetric constraints for OARs and Targets.

A reference to the images used to create ROIs is provided in the Contour Image Sequence within the RT Structure Set IOD. Population of the Contour Image Sequence, i.e., reference to the image (plane) used to create ROI contours, is required by the IHE-RO Basic RT Objects (BRTO) Integration Profile.
5.3.3 Other Considerations for DICOM Dose and Imaging Specification

The radiation oncology community would benefit from distinct nomenclature for a wide range of attributes of structures, but currently faces impractical character string representation or unworkable challenges with length constraints. Examples include details of the following:

- Specific dose of relevance pertaining to the prescribed dose and fractionation.
- Derivation of one structure from another, along with associated Boolean operations and margins (e.g., creation of ITV structures).
- Source image systems and considerations used in constructing the volumes (e.g., combined CT and MR information for optic structures, combined used of MR, CT, and PET to define target volumes).
- Specification of 4DCT used for treatment, including individual or averaged phases (e.g., MIP) used for delineating target and organs at risk.
- Requirements defined by ICRU Report 83 (p. 42) for reporting on a GTV:
  - The location and tumor extent according to TNM (GP)
  - The imaging type on which the GTV is delineated
  - The point in time (e.g., during a series of RT sessions) the image was made and on which the delineation is based.

### Table 4. Defined terms for interpreted types from DICOM.

<table>
<thead>
<tr>
<th>Interpreted Type</th>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regions of Interest (ROI)</td>
<td>AVOIDANCE</td>
<td>Region in which dose is minimized</td>
</tr>
<tr>
<td></td>
<td>BOLUS</td>
<td>Material layered onto the patient to increase high dose provided by external beam therapy to the patient’s skin surface</td>
</tr>
<tr>
<td></td>
<td>CAVITY</td>
<td>Patient anatomical cavity</td>
</tr>
<tr>
<td></td>
<td>CONTRAST_AGENT</td>
<td>Volume into which a contrast agent has been injected</td>
</tr>
<tr>
<td></td>
<td>CTV</td>
<td>Clinical Target Volume (as defined in ICRU 50/62)</td>
</tr>
<tr>
<td></td>
<td>EXTERNAL</td>
<td>External patient contour</td>
</tr>
<tr>
<td></td>
<td>GTV</td>
<td>Gross Tumor Volume (as defined in ICRU 50/62)</td>
</tr>
<tr>
<td></td>
<td>IRRAD_VOLUME</td>
<td>Irradiated Volume (as defined in ICRU 50/62)</td>
</tr>
<tr>
<td></td>
<td>ORGAN</td>
<td>Patient organ</td>
</tr>
<tr>
<td></td>
<td>PTV</td>
<td>Planning Target Volume (as defined in ICRU 50/62)</td>
</tr>
<tr>
<td></td>
<td>REGISTRATION</td>
<td>Registration ROI</td>
</tr>
<tr>
<td></td>
<td>TREATED_VOLUME</td>
<td>Treated volume (as defined in ICRU 50/62)</td>
</tr>
<tr>
<td>Point of Interest (POI)</td>
<td>MARKER</td>
<td>Patient marker</td>
</tr>
<tr>
<td></td>
<td>ISOCENTER</td>
<td>Treatment isocenter to be used for external beam therapy</td>
</tr>
<tr>
<td>Brachytherapy</td>
<td>BRACH_CHANNEL</td>
<td>Brachytherapy channel</td>
</tr>
<tr>
<td></td>
<td>BRACHY_ACCESSORY</td>
<td>Brachytherapy accessory device</td>
</tr>
<tr>
<td></td>
<td>BRACHY_SRC_APP</td>
<td>Brachytherapy source applicator</td>
</tr>
<tr>
<td></td>
<td>BRACHY_CHNL_SHLD</td>
<td>Brachytherapy channel shield</td>
</tr>
<tr>
<td>Other Type</td>
<td>SUPPORT</td>
<td>External patient support device</td>
</tr>
<tr>
<td></td>
<td>FIXATION</td>
<td>External patient fixation or immobilization device</td>
</tr>
<tr>
<td></td>
<td>DOSE_REGION</td>
<td>ROI to be used as a dose reference</td>
</tr>
<tr>
<td></td>
<td>CONTROL</td>
<td>ROI to be used in control of dose optimization</td>
</tr>
</tbody>
</table>
6. Color Specification

The task group survey investigated whether or not standard colors were used for structure templates and DVH curves. The selection of specific colors and display parameters (e.g., filled-in, semi-transparent, wire-contour) was highly variable among institutions. Standard coloration of structures at institutions facilitated plan quality assurance (QA) and interpretation of plans for peer review and documentation. However, standardization of the colors across institutions is not easily achievable because:

1. Treatment planning and plan review systems have limited and variable color options.

2. Visibility of contours overlaid on tissues on CT images depends on the density of the contoured structure and the density of the surrounding structures. Even if the colors are appropriate for CT images, the transferred or displayed colors on a different modality may not be visible anymore.

3. Visibility of contours also depends on the dose display (isodose lines or color wash). For example, different colors are needed to distinguish the two—the target and the prescription isodose line. Note that color-blind people make up 10% of a population. Different formats (solid line vs dashed line) should also be considered to improve visibility.


Standardization of colors was seen as valuable, but notions of the “right” color were highly variable. The task group elected not to make specific recommendations for colors at this point in time because (1) specific color coding is not currently necessary to improve the ability to automate exchange of data among institutions, (2) there are challenges as outlined above, and (3) there is currently a lack of uniformity among clinical trials on this parameter. In general, institutions can improve safety and consistency by defining and implementing simple rules for the use of color to make plans more easily interpretable. Using similar colors for isodose lines and structures when the dose abuts the structure is not recommended. As the nomenclature is adopted into clinical practice and trials to enable sharing of standardized templates and scripts that reduce work, convergence on expectations for color will begin to occur implicitly.

7. Recommendations for Non-Target Structure Nomenclature

7.1 Approach

TG-263 defined the following set of guiding principles for creating structure names. As new structures are added, following these principles ensures names that are operable with current vended systems and consistent in structure. This enables the use of computer algorithms to parse names.

The primary objective in defining a nomenclature is to reduce variability in naming. Variation is the principle barrier to developing automated solutions for accurate extraction, exchange, and processing of data. Variation in naming occurs over time between individuals and among institutions and vendors. The second objective for a nomenclature is straightforward adoption into current practice. For example, the use of just three hexadecimal characters would enable numeric coding of 4096 structures, leaving ample room to encode other details about the structures and to also be language neutral. However, proposing that users label the brain as “06E” instead of “Brain” would fail, utterly. To succeed in reducing data variability while being practical, there were a few situations where it was necessary to sacrifice internal consistency or strict adherence to a set of ideals in order to define a pragmatic schema.
7.2 Guiding Principles for Non-Target Nomenclature

1. All structure names are limited to 16 characters or fewer to ensure compatibility with a majority of vended systems.

2. All structure names must resolve to unique values, independent of capitalization. This ensures that systems with case-insensitive formats do not result in overlapping definitions.

3. Compound structures are identified using the plural, i.e., the name ends with an ‘s’ or an ‘i’ as appropriate on the root structure name (e.g., Lungs, Kidneys, Hippocampi, LNs (for all lymph nodes), Ribs_L).

4. The first character of each structure category is capitalized (e.g., Femur_Head, Ears_External).

5. No spaces are used.

6. An underscore character is used to separate categorizations (e.g., Bowel_Bag).

7. Spatial categorizations for the primary name are always located at the end of the string following an underscore character (e.g., Lung_L, Lung_LUL, Lung_RLL, OpticNrv_PRV03_L):
   a. L for left
   b. R for Right
   c. A for Anterior
   d. P for Posterior
   e. I for Inferior
   f. S for Superior
   g. RUL, RLL, RML for right upper, lower and middle lobe
   h. LUL, LLL for left upper and lower lobe
   i. NAdj for non-adjacent
   j. Dist for distal, Prox for proximal

8. A consistent root structure name is used for all substructures (e.g., SeminalVes and SeminalVes_Dist have a consistent root structure name, but SeminalVesicle and SemVes_Dist do not have a consistent root structure name).

9. Standard category roots are used for structures distributed throughout the body:
   a. A for artery (e.g., A_Aorta, A_Carotid)
   b. V for vein (e.g., V_Portal, V_Pulmonary)
   c. LN for lymph node (e.g., LN_Ax_L1, LN_IMN)
   d. CN for cranial nerve (e.g., CN_IX_L, CN_XII_R)
   e. Glnd for glandular structure (e.g., Glnd_Submand)
   f. Bone (e.g., Bone_Hyoid, Bone_Pelvic)
   g. Musc for muscle (e.g., Musc_Masseter, Musc_Sclmast_L)
   h. Spc for Space (e.g., Spc_Bowel, Spc_Retrophar_L)
   i. VB for vertebral body
   j. Sinus for sinus (e.g., Sinus_Frontal, Sinus_Maxillary)
10. Planning organ at risk volumes (PRV) are indicated with PRV following the main structure separated by an underscore (e.g., Brainstem_PRV). Optionally, the uniform expansion used to form the PRV from the main structure in millimeters is indicated with two numerals (e.g., SpinalCord_PRV05, Brainstem_PRV03,) unless the result exceeds the character limit. For example, OpticChiasm_PRV03 is 17 characters and may be truncated to OpticChiasm_PRV3.

11. Partial structures are designated by appending a ‘~’ character to the root name (e.g., Brain~, Lung~_L). This designator should be used to ensure a contoured structure is not misinterpreted as a whole organ when such a misinterpretation could have clinical implications (typically parallel organs). A use case example is a CT scan not long enough to include the full lung volumes, for which Lungs~ indicates the contoured pair of lungs is only a portion of the complete structure.

12. If a custom qualifier string is to be used, it is placed at the end after a ‘^’ character (e.g., Lungs^Ex).

13. Establish a Primary and a Reverse Order name for each structure.
   a. **Primary Name.** Reading left to right, the structure categorization proceeds from general to specific with laterality on the end. As a result, alphabetically sorted structure names produce a list that is grouped by organ (e.g., Kidney_R, Kidney_Cortex_L, Kidney_Hilum_R). The Primary Name is recommended as the standard choice.
   b. **Reverse Order Name.** Reverse the order of Primary Name. Some vended systems allow longer strings but have displays that default to show fewer than 16 characters. The Reverse Order Name increases the likelihood that sufficient information can be displayed to safely identify the correct structure. For example, R_Hilum_Kidney would display as R_Hilum_Ki if the vendor’s report only showed the first 10 characters. It is suggested that Reverse Order Name be limited to situations where vendor system constraints prevent safe use of Primary Name.

14. Camel case (a compound word where each word starts with a capital letter and there is no space between words such as CamelCase) is only used when a structure name implies two concepts, but the concepts do not appear as distinct categories in common usage (e.g., CaudaEquina instead of Cauda_Equina) because there are not several examples of Cauda_xxxxx. Camel case names for primary and reverse order names are identical.

15. Structures that are not used for dose evaluation (e.g., optimization structures, high/low dose regions) should be prefixed with a ‘z’ or ‘_’ character so that an alphabetical sort groups them away from structures that are used for dose evaluation (e.g., zPTVopt). Selection of ‘z’ to designate dose evaluation structures is suggested.

Very few vendor systems do not allow capital letters in the fields identifying structures. Since the vast majority do, capitalization was used as part of the guiding principles (item 4). Item 2 assures that if a system does not allow capitalization, the character string will still be unique and can be programmatically matched.

Potential conflicts for the use of ‘A’ in indicating an arterial structure and in indicating an anterior portion of a structure (e.g., A_Carotid_A) were noted and discussed. In practice, the need to identify an anterior surface is rare. For example, NRG currently does not make use of this descriptor for any of its trials. Alternative spatial designators either presented similar issues (e.g., D for dorsal and V for ventral) or violated standard medical practices (e.g., F for front and B for back). Use of alternative indicators for artery and vein were also discussed. The use of A and V to indicate artery and vein is in
wide use, and no single character alternatives were evident. Since no examples existed with this potential conflict, the group elected to accept the potential conflict for the current version of the guidelines.

Permitting the use of camel case for a few specific structures was discussed. In Primary Name values, concepts are ordered from general to specific, proceeding left to right. Reverse Order Name values invert the ordering, e.g., Bag_Bowel for Primary Name and Bowel_Bag for Reverse Order Name. The utilization of camel case provided a means to not violate this principle and maintain compatibility with common usage for the relatively small number of structures involved (e.g., CaudaEquina and OpticChiasm are rendered the same for both Primary Name and Reverse Order Name). The potential safety impact of this usage of camel case was considered. No major risks were identified, and the group felt that assuring the same value of both name values for those few special cases was seen as supporting patient safety.

Whether or not to allow for two naming values for each structure was considered from a practical perspective. The recommended standard is the Primary Name. Vendors are encouraged to modify their systems so that the full 16-character lengths of standard structure names are displayed in applications and reports. Reverse Order Name values are only for those systems unable to support the Primary Name values until further changes are made in those systems. As these changes are made and safety risks introduced by concatenating names eliminated, usage should converge on the Primary Name.

In evaluating treatment plan dose distributions, tolerance levels are determined by tissue or organ type. By using standard category root names, an alphabetic sort of the Primary Name structures will group those with similar tolerances. This is particularly valuable when structure names may not be commonly used and could be at risk for misinterpreting the structure type (e.g., Mesenteric vs A_Mesenteric, Iliac vs A_Iliac, or I vs CN_I). However, there are a few structures that are in routine use where forcing use of the category root name could impede adoption (e.g., Parotid vs Glnd_Parotid) of the nomenclature. In those few cases, the task group chose to accept the internal inconsistency of forgoing the root name (e.g., Parotid) in order to maintain the overarching objectives of reducing variability in nomenclature and high adoptability into clinical practice.

7.3 Structure Nomenclature List
A spreadsheet was created to facilitate look up of structures. Structures were categorized, described, and assigned official values and linked to the corresponding Foundations of Medical Anatomy identification number (FMAID). Currently, the nomenclature defines 717 structures. The complete list can be found on the AAPM website for TG-263 at http://www.aapm.org/pubs/reports/RPT_263_Supplemental/.

The list will be a living document with periodic updates. In addition, all guidelines for structure naming and for DVH metrics are included in the document.

There are nine column headings in the spreadsheet used to aid in finding the names of structures of interest:

1. Target Type: Anatomic, Non-Anatomic (e.g., catheter), Derived (e.g., Body-PTV)
2. Major Category: General organ category
3. Minor Category: Additional distinguishing category
4. Anatomic Group: Region of the body where structure is located
5. N Characters: Number of characters in the name
6. TG263–Primary Name: Preferred naming
7. TG263–Reverse Order Name: Alternative naming
8. Description: Additional description of the structure
9. FMAID: Identification number of structure in the FMA most closely related
8. Recommendations for Target Structure Nomenclature

8.1 Approach

Surveys of member responses for target naming strategies revealed that clinics use a very complex set of concepts: ICRU and other types, target classifiers for primary and nodal volumes, enumeration of volumes when there are several structures, dose, basis structures, imaging modality used to create, etc.

Clinics did not attempt to represent all concepts, but selected those few considered most important to their process. Within an individual clinic, different naming strategies could be used for different treatment sites or physicians.

Task Group 263 determined that it could not come to consensus to define a single standard for all use cases and clinics that spanned the numerous concepts for a target name and also meet character string constraints. However, TG-263 did establish a set of guiding principles to specify where and how a concept should appear if it is represented in the target name. Therefore, Task Group 263 established a set of guiding principles for target nomenclature.

This approach enables construction of computer algorithms to parse the names or to automatically create names based on concepts selected by users. Users choose the supplemental information to incorporate into target names, and these guiding principles ensure that computer programs can recognize these names for quality and research endeavors. While these principles accommodate the major-
ity of encountered names, they cannot accommodate all. TG-263 recommends using the ‘\(^{*}\)’ character to designate supplemental information not incorporated in the current guidelines.

### 8.2 Guiding Principles for Target Nomenclature

1. The first set of characters must be one of the allowed target types:
   - GTV
   - CTV
   - ITV
   - IGTV (Internal Gross Target Volume—gross disease with margin for motion)
   - ICTV (Internal Clinical Target Volume—clinical disease with margin for motion)
   - PTV
   - PTV! for low-dose PTV volumes that exclude overlapping high-dose volumes (See the section discussing segmented vs non-segmented PTVs.)

2. If a target classifier is used, place the target classifier after the target type with no spaces. Allowed target classifiers are listed below:
   - n: nodal (e.g., PTVn)
   - p: primary (e.g., GTVp)
   - sb: surgical bed (e.g., CTVsb)
   - par: parenchyma (e.g., GTVpar)
   - v: venous thrombosis (e.g., CTVv)
   - vas: vascular (e.g., CTVvas)

3. If multiple spatially distinct targets are indicated, then Arabic numerals are used after the target type + classifier (e.g., PTV1, PTV2, GTVp1, GTVp2).)

4. If designation of the imaging modality and sequential order in the image set need recording for adaptive therapy, then the nomenclature follows the type/classifier/enumerator with an underscore and then the image modality type (CT, PT, MR, SP) and number of the image in the sequence (e.g., PTVp1_CT1PT1, GTV_CT2).

5. If structure indicators are used, they follow the type/classifier/enumerator/imaging with an underscore prefix and are values from the approved structure nomenclature list, (e.g., CTV_A_Aorta, CTV_A_Celiac, GTV_Preop, PTV_Boost, PTV_Eval, PTV_MR2_Prostate).

6. If dose is indicated, the dose is placed at the end of the target string prefixed with an underscore character.
   - The task group strongly recommends using relative dose levels instead of specifying physical dose
     - High (e.g., PTV_High, CTV_High, GTV_High)
     - Low (e.g., PTV_Low, CTV_Low, GTV_Low)
     - Mid: (e.g., PTV_Mid, CTV_Mid, GTV_Mid)
Mid+2-digit enumerator: allows specification of more than three relative dose levels (e.g., PTV_Low, PTV_Mid01, PTV_Mid02, PTV_Mid03, PTV_High). Lower numbers correspond to lower dose values.

- If numeric values for the physical dose must be used, then specification of the numeric value of the dose in units of cGy is strongly recommended (e.g., PTV_5040).

- If numeric values for physical dose must be used and these must be specified in units of Gy, then ‘Gy’ should be appended to the numeric value of the dose (e.g., PTV_50.4Gy). For systems that do not allow use of a period, the ‘p’ character should be substituted (e.g., PTV_50p4Gy).

7. If the dose indicated must reflect the number of fractions used to reach the total dose, then the numeric values of dose per fraction in cGy, or in Gy with the unit specifier, and number of fractions separated by an “x” character are added at the end (e.g., PTV_Liver_2000x3 or PTV_Liver_20Gyx3).

8. If the structure is cropped back from the external contour for the patient, then the quantity of cropping by “-xx” millimeters is placed at the end of the target string. The cropping length follows the dose indicator, with the amount of cropping indicated by xx millimeters (e.g., PTV_Eval_7000-08, PTV-03, CTVp2-05).

9. If a custom qualifier string is used, the custom qualifier is placed at the end after a ‘^’ character (e.g., PTV^Physician1, GTV_Liver^ICG).)

10. If it is not possible to follow the guidelines and remain within the 16-character limit, then preserve the relative ordering but remove underscore characters, progressing from left to right as needed to meet the limit (e.g PTVLiverR_2000x3.) This last resort scenario undermines the use of automated tools.

Two distinct methods are used for sequential treatments of the same target volume (Guiding Principle #3). Some institutions used sequential numbers as the patient returns for future treatment courses for the same PTV, (e.g., PTV1 and PTV2 for the original course and PTV3 and PTV4 for lung metastasis treated in a later course). In contrast, other institutions numbered sequentially for targets treated within the course, independent of historical treatments (e.g., PTV1 and PTV2 for the original course and PTV1 and PTV2 for lung metastasis treated in a later course) used the same nomenclature for re-irradiation of the same (not spatially distinct) target. TG-263 does not define a recommended sequential numbering method. Practices should ensure their method is self-consistent and guard against the incorrect summing of total doses.

Dose units used when categorizing target structures with dose information was extensively discussed. As stated above, the primary objective for a nomenclature is to reduce variability. The secondary objective is facilitating adoptability into clinical practice. Prescription of doses in units of cGy is common in the United States, is the current recommendation of the ASTRO working group on prescriptions, and is supported by analysis of RO-ILS data\textsuperscript{19}. Prescription in units of Gy is more common in European countries and is also used in some large institutions in the US. All groups advocating one over the other cite safety as a primary factor. While it is highly desirable to specify a single answer in the standard, the most important point for safety and data access is ensuring unambiguous communication. Since it was not possible to identify a single dose unit with wide global adoption, an approach compatible with each was identified.

The use of relative dose (e.g., PTV_High) was the primary recommendation if dose information is conveyed in the target name. This approach has several advantages. First, it is independent of the physical dose units used at various institutions, so there is no need to specify cGy (e.g., PTV_6660) or
Gy (e.g. PTV_66.6Gy). Second, it is not uncommon for a prescription to be changed in the course of treating a patient. In that case, if physical dose units were used, the structure name would have to be renamed with the correct dose to convey the correct information (e.g., change from PTV_7560 to PTV_7380). Without this change, the name could convey conflicting information with respect to the current prescription, presenting both logistic and safety issues. Third, when mining dosimetric data, relative dose names greatly improve the speed, accuracy, and composability of queries to extract needed information. For most disease sites, only two or three target structure names are needed (e.g., PTV_High, PTV_Mid, PTV_Low), so extracting the median dose to these structures, along with the number of fractions treated, provides a great deal of information on target structure doses with minimal effort. On the other hand, needing to first identify all dose levels from the structure name and then reconstructing relative dose levels within each plan from the physical doses specified in the name is much more difficult and prone to error.

If physical doses are used, the numeric value should be defined in units of cGy. The use of cGy is consistent with recommendations of ASTRO and RO-ILS. Enabling unambiguous standardized communication of dose in the name promotes adoptability of the nomenclature in a broad range of national and international clinics. For clinics that currently use Gy for prescriptions, then the physical doses in Gy should be communicated explicitly with the addition of ‘Gy’ as a suffix for clarity in communication. This approach uses a similar number of characters for each dose unit, and when Gy is used it is consistent with the recommendations for DVH metrics, as described in the next section.

9. Recommendations for Dose Volume Histogram Metrics

9.1 Approach

Very few examples of standardized nomenclatures exist for the full set of dose and volume metrics used in practice. Providing specificity on exactly what is measured, input parameters, units used for dose and volume—all in a format that can be parsed with regular expression operators—improves the ability to use computer algorithms to automate calculation. The ability to incorporate radiobiological metrics and units is also important. Figure 4 illustrates the recommended DVH nomenclature.
9.2 Guidelines for DVH metrics

- Units or label for what is measured (output) are specified at the end of the string, enclosed in square brackets.
  - Dose: Gy or % where percent (%) references dose prescribed to PTV_High structure type
  - Volume: cc or % where percent (%) references volume of structure
  - Equivalent 2 Gy: EQD2Gy

- Measurement type is specified at the beginning of the string. Units or label for where on the curve the point is measured (input) are specified.
  - Vx: volume of sub volume receiving $\geq$ dose x. Dose units or label are specified (e.g., V20Gy[%], V95%[%], V20Gy[cc])
  - Dx: minimum dose received by the hottest sub volume x. Volume units or label are specified (e.g., D0.1cc[Gy], D95%[%])
  - CVx: volume of sub volume receiving $\leq$ dose x. Dose units or label are specified (e.g., CV10.5Gy[cc], CV95%[cc])
  - DCx: maximum dose received by the coolest sub volume x. Volume units or label are specified (e.g., DC0.1cc[Gy], DC1%[Gy])

- If calculation parameters for the metric are required, they are enclosed in parenthesis in front of the square brackets defining output units or label (e.g., V50EQD2Gy(2.5)[%]).
Conventional DVH metrics correspond to points receiving a certain dose or more. In lung, V20Gy[%] is the percentage of lung volume that receives 20 Gy or more. Conversely, details about points receiving a certain dose or less use nomenclature with an inserted “C” for complement or cold to qualify the sub volume\textsuperscript{21}. Thus for liver SBRT, CV15Gy[cc] is the absolute volume that receives 15 Gy or less. For example, DC700cc[Gy] selects the 700 cc sub volume that receives the lowest overall dose and reports the highest dose in that sub volume.

Task Group 263 discussed and acknowledged the differences in recommendation for use of cGy dose units in defining target structure names (e.g., PTV_4500) compared to the recommendation for use of Gy for DVH metrics (e.g., V20Gy[%] vs V2000cGy[%]). The nomenclature recommendations were in keeping with routine clinical practice for many clinics and represented minimal deviation from less specific values commonly encountered in the literature (e.g., V20 vs V20Gy[%]). Further, while safety in minimizing risk of miscommunication about target volumes and allowed free text characters in vended systems was significant in the discussion of target structures (e.g., PTV_5040 vs PTV_50.4), these safety issues were not found for the DVH metrics. The nomenclature extends use specification of input and output units with addition of the EQD2Gy dose unit specifying dose delivered in 2 Gy fractions calculated to have the same radiobiological effect with the linear quadratic model and a specified value of $\alpha/\beta$. Calculation parameter values, including $\alpha/\beta$, are enclosed in parenthesis before the output units. Nomenclature does not currently specify the ordering of parameter values for particular calculations. This approach minimizes naming constraints of the evolving types of radiobiological calculations, or parameters used, while preserving a consistent representation of involved units and explicit indication parameter values. Designation of algorithm may also be included as a parameter in the parenthesis.

Examples of radiobiological calculations using EQD2Gy are listed below:

- Maximum equivalent 2 Gy dose calculated with an $\alpha/\beta$ ratio of 4: Max(4)[EQD2Gy].
- Equivalent 2 Gy dose encompassing 90% of a target volume, calculated with an $\alpha/\beta$ ratio of 10: D90%(10)[EQD2Gy].
- Percentage volume of a structure receiving 50 EQD2Gy using an $\alpha/\beta$ of 3 vs 10: V50EQD2Gy(3)[%] vs V50EQD2Gy(10)[%].
- Distinguishing use of the linear-quadratic (LQ) vs the linear-quadratic-linear (LQL) model in calculating the 2Gy equivalent dose encompassing 95% of a structure when an $\alpha/\beta$ of 10 is used: D95%(10,LQ)[EQD2Gy] vs D95%(10,LQL)[EQD2Gy].

Research settings use a wide range of radiobiological metrics. Examples include Tumor Control Probability (TCP), Normal Tissue Complication Probability (NTCP), and Biologically Effective Dose (BED). These are not typically encountered in clinical settings at this time. Models continue to evolve defining new types and parameters. Approaches currently in use at several member institutions were compatible with the guideline recommendations for enclosing calculation parameters in parenthesis (e.g., NTCP(LQL, $\alpha/\beta = 2.5$, TD50 = 40, n = 1.0, m = 0.13), NTCP(40, 1.0, 0.13), BED($\alpha/\beta = 10$), BED(10)). The task group did not make specific nomenclature recommendations for these radiobiological metric types and parameters.

### 10. Recommendations for Distinguishing Metrics of Segmented vs Non-Segmented Target Structures

The reported DVH metrics for multiple PTV volumes treated to differing dose levels should define if the lower-dose PTV volumes exclude (segmented) or include (non-segmented) the higher-dose PTV volumes. For example, a low-dose nodal volume may be treated to 5000 cGy (PTV_5000), while a
A boost volume within that nodal volume is treated to 7000 cGy (PTV_7000). The following discussion does not apply to structures created to achieve conformal dose distributions during IMRT/VMAT optimization.

Both segmented and non-segmented volumes can be valuable for dose evaluation. The concern is that the clinical PTVs used to evaluate the plan may not be clearly delineated as segmented or non-segmented PTV in the nomenclature. This is illustrated in Figure 5. For non-segmented low-dose PTVs, the DVH typically shows a “foot” of the overlap with the high-dose PTV volume. Segmented low-dose PTVs have a long high-dose tail. The nomenclature needs to clearly delineate between segmented and non-segmented PTV volume for pooling data. Either approach can work, but if the standards vary among institutions, then metrics such as PTV_5000: V115[%] would be significantly different, depending on the approach. For example, if the PTV_5000 is not segmented and contains PTV_7000, V115[%] would necessarily be high, reflecting the ratio of volumes, whereas for a segmented PTV_5000, V115[%] would be significantly lower.

Since non-segmented PTVs retain information on overlaps relevant to dose evaluation, whereas segmented PTVs do not, many institutions typically use non-segmented volumes. To retain the ability to use both approaches, Task Group 263 recommended that the default assumption is non-segmented target volumes. If a segmented volume is used (i.e., exclusion of overlap with high-dose sub volumes), then its target type should include a ‘!’ character suffix to clarify (e.g., GTV!, CTV!, PTV!). This should be exceedingly rare for GTV and CTV structures.

**11. Recommendations to Vendors**

Vendors have a critical role in facilitating safe and effective care of patients receiving radiation therapy. This role includes the provision of platforms that allow for implementation of widely accepted nomenclature standards, such as AAPM TG-263. The full range of information clinicians would like to convey about structures used in plans exceeds the limited capabilities of a character string with the current IDs. These limitations apply to a wide range of vended system categories (e.g., treatment plan-
The deliberations of the task group considered two overall objectives: 1) a nomenclature that could be widely adopted in the vended systems as they currently exist and 2) new definitions of data element representations for encapsulating a fuller representation of the data.

One important consideration for a standardized nomenclature is the adoptive ability across all available platforms. Currently, DICOM-RT is the standard for data communication across the radiation therapy process. Therefore, TG-263 recognizes that an updated nomenclature cannot exceed or violate any data limits imposed by DICOM. Some consideration may include the number of characters to define the ROI Name string and the use of special characters (see section 4.5). In some cases, a planning system has stricter requirements than DICOM because of the effect of special characters on a vendor-specific database, data structure, user interface, or formatting of custom reports.

Two desirable features of a nomenclature system are:

- Defined structure is human-readable.
- Sufficient information avoids ambiguity between similar items in the system.

However, the human readability must be resolved with the intent for the nomenclature to be logical from a data analysis standpoint, readily processed or deconstructed for analysis, and integrated with automated systems.

TG-263 summarizes the main challenges of designing a system:

- The information on structure identification, relationships to imaging modalities as use of adaptive therapy increases, motion assessments, etc. currently exceed the capability of a single character string to encapsulate all parameters in a clinically usable fashion. Capabilities of vended systems need to be expanded to capture a wider set of properties to characterize structures and to display the information.
- Clinical implementation of a standard nomenclature is hindered by the existing free-text naming of the structures in most commercial systems.
- Multiple versions of the same anatomical structure for a specific patient can create a challenge. This scenario primarily happens when multiple image sets define the same structure on each image set, representing the same anatomical entity (e.g., image sets at different time points).
- Structure contour delineation on image sets is an important tool for treatment planning, appropriate treatment delivery, and adjustment of treatment plans. Contours define critical regions and target volumes for redefining and adapting our treatment plans. They are also used for tracking changes, assessing the meaning of the images within the regions, and determining prognostic indications from multiple image modalities. Thus, accurate documentation of the intent and provenance of structures and their associated image sets with easy retrieval is a necessity.
- The system should be as intuitive and efficient as possible to maximize adoption by its clients and enhance comparative research analysis.
- There is often no option to add formal semantics or codes (e.g., such as an FMA ID) to a structure. Vendors should implement the use of DICOM coding attributes to identify and categorize structures.

The TG-263 nomenclature recommendations can be implemented using current vended systems and can improve the current situation. However, vendors need to develop or update their systems to capture a wider set of properties for characterizing structures and displaying the information. The following are general recommendations for vended system developments:
1. The user interface should incorporate tools to facilitate the inclusion of standard nomenclature and sufficient space for adding newly delineated ad-hoc structures of interest. The tools for the standard nomenclature may range from suggestive auto-text to direct specification through selection lists of available names.

2. Systems should provide system administrators latitude to restrict nomenclature choices to comply with external standards (e.g., TG-263) and local standards as they evolve and as clinics are ready to implement them.

3. A wide range of attributes for structures are relevant for both research and clinical purposes. The system should allow standardization of attribute identifiers and capture of values to augment the single string name, including:
   a. versions
   b. linkage of target structure volumes to prescription elements (dose and fractionation)
   c. relationship of structures among data sets (e.g., PTV_1 corresponds to the same target region in the structure set used for the first course and for a subsequent recurrence)
   d. identification of the individual who created the structure
   e. full or partial volume (e.g., rectum near PTV vs full rectum)
   f. image data set (including phase on 4DCT) used to create the structure (e.g., created on registered MR scan and copied over to CT scan for planning)
   g. motion status (e.g., ITV created from 4DCT)
   h. linkages to standardized codes (e.g., diagnosis code (ICD9/10), oncology code (ICD-O), anatomical concept code (FMA))
   i. dose tag (e.g., name structure PTV_High and define dose tag = 7000 cGy)
   j. margins used to create the structure
   k. image modality characteristics
   l. visualization characteristics (e.g., window and level)
   m. factors and operations used to define derived structures (e.g., structure C is Boolean OR of structure A and structure B)

4. Systems should allow the definition and linkage of multiple structures, but maintain a requirement that only one structure can be definitive per image set. For example, an anatomical entity may be identified in multiple longitudinal image sets that track changes in volume or shape over time. Second, one structure is defined on multi-modality image sets that link the image features, such as PET affinity to density and perfusion to better characterize the anatomy and physiology in a comprehensive way.

5. Systems should be designed to significantly improve the management of image segmentation for the multitude of uses in radiotherapy. As examples, systems should preserve changes to contours over time, maintain flexibility to compare with different imaging modalities, and allow for links between image sets for a given patient over time. Such functionality adds value as multiple plans and imaging data sets are used with each patient, such as with adaptive radiotherapy.

6. Systems should be designed to allow definition of algorithms or scripts to define names of target structures to reflect the task group recommendations for target structures.
7. Systems should enable writable scripting that would enable creation of plans and structures adhering to standardizations to improve consistency, safety, and interoperability for data sharing. Writable scripts enable end users to create and share programs that design, edit, and optimize treatment plans consistent with standards as they are introduced. For example, it should be easy to import/export and use tables that incorporate the desired nomenclature, attributes, or identifiers in creation of treatment plans.

8. Investigation of the use of natural language processing (NLP) mapping free-text input values to standard nomenclature values would improve ease of use for end users.

9. Systems should match DICOM standards in determining allowed characters and allowed storage and display string lengths. The current compromise of 16 characters for structure names is far shorter than the current DICOM standard of 64 characters.

Figure 6 is an example of a general target structure concept with related attributes and associations between related structures. A conventionally fractionated right lung primary is the use case. Note that multiple attributes—such as anatomic location, disease code, and dose tags—are attached, along with associated structures (GTV, PTV, etc.) and their linking properties (deformable transfer, margins, dataset of origin, etc.) are also included in the potential design.

Implementing many of the naming concepts described here requires significant effort by vendors. Furthermore, some concepts require development of standards that either do not exist or are not yet mature. However, implementing structure naming controls in treatment planning systems should require minimal changes to the software architecture.

A number of treatment planning systems have scripting capability. It is important that scripting allows both read and write capabilities so that users can build automated tools to reduce effort and improve quality assurance of compliance with standardizations. In the near term, user groups can sup-

![Figure 6. Example of an enhanced target definition concept for vended systems to consider. Note the various attributes and linking properties that may be applied to describe a structure outside of the structure name itself. Margins specified are only for illustration of concepts to capture and are not general recommendations for values.](image-url)
port nomenclature standardization through development of validation scripts. These efforts will fur-
ther support data integrity in clinical trials as described in AAPM Task Group 113.13

A standard format for communicating the set of structure names to be used for a clinical trial or
clinical scenario is currently in development (DICOM Supplement 196). Broad implementation of this
specification to create and distribute templates for structure identification in commercial image seg-
mentation and treatment planning systems is expected to improve the consistency of structure names
and provide a means to distribute codes for structure identification and categorization. Manufacturers
are encouraged to support implementation of this standard as it becomes available.

This group recommends that vendors place a priority on the development of systems that enable
users to enforce compliance with specific nomenclatures (e.g., TG-263 guidelines) and that the sys-
tems allow the nomenclature rules to be configured by individual sites. The guidelines of TG-263 pro-
mote goals for safety, clinical efficiency, clinical trials, and utilization of Big Data resource systems
that are of common interest to users, vendors, and funding agencies to support advances in patient
care. The group recommends that vended systems be made to follow TG-263 guidelines within a two-
year period.

12. Nomenclature Pilot Study Design and Results

12.1 Pilot Study Design

Change is hard. Implementing the new standards in the clinic requires addressing learning curves,
implications for existing documentation, additional work for staff, process changes, etc. It is important
to know that new recommendations can be successfully implemented in clinical settings.

Before finalizing recommendations, the preliminary nomenclature was piloted by a group of five
institutions for head and neck patients. The pilot study was used to identify any hindrances to imple-
mentation, such as an overlooked anatomical site. Members also reported the ease or difficulty of
adopting nomenclature so improvements can be made before widespread adoption of the standards.
Groups were asked to conform to the recommendations for non-target structures and explore willing-
ness to adopt the guidelines for targets.

Several institutions that piloted the nomenclature also developed scripts and xml files to facilitate
adoption of the nomenclature.

12.2 Pilot Study Results

Five groups—NRG (Philadelphia, PA), MD Anderson Cancer Center (Houston, TX), University of
Florida (Jacksonville, FL), Karmanos Cancer Center (Detroit, MI), and the University of Michigan
(Ann Arbor, MI)—participated in the pilot study. A sixth group, Princess Margaret Cancer Centre
(Toronto, Ontario), piloted the nomenclature for breast patients. Several of the piloting institutions had
conducted internal reviews of naming variability in their current systems. The ability to converge on a
single system that eliminated the variability and improved data exchange with the NRG and other
institutions was generally found to be more compelling than local preferences for naming syntax.

Pilot groups reported little difficulty in implementing the nomenclature. For example, although the
pilot was targeted for a subgroup of patients with head and neck cancer, several of the institutions
phased in adoption of the entire nomenclature for all disease sites. The nomenclature was readily
adopted into the NRG standards as new trials were added. A common approach for easing the transi-
tion was the use of structure templates or scripting capabilities built into treatment planning systems to
enable pre-populating the lists of structures seen by physicians and dosimetrists. In routine practice,
when a planner wonders what name to choose for a structure, scripts that automate creation of plans
and naming of structures could make using the standardized answer also the easy answer. Three
groups adopted the nomenclature in conjunction with upgrades to their radiation oncology information systems.

Some vendors incorporated the developing consensus nomenclature from the task group into their products to facilitate the ability of users to standardize. Earlier versions of some vendor systems borrowed nomenclature from published and unpublished nomenclatures that had been previously developed by members. Incorporations of TG standards into vended systems was very helpful for institutions piloting the nomenclature.

Some treatment planning systems include the ability to use templates and scripts to facilitate introduction of standardizations into clinical practice. Among our pilot sites, two were in use. Examples for these systems are described below for practical illustration. This does not constitute an endorsement of either; there may or may not be better tools in other systems. Manufacturers are encouraged to support adoption of the nomenclature by making it available in their systems for all users as systems are purchased or upgraded. They are further encouraged to make templates and scripts that facilitate implementation of this nomenclature available when systems are purchased.

The use of nomenclature can be supported by different software versions in a way to support user adoption. For example, ARIA version 13.x provides a Structure Dictionary which includes Foundations of Medical Anatomy identification numbers (FMAIDs) if they exist. Users edited labels, default IDs, and synonyms for items most closely matching the nomenclature. Users can define specific treatment sites (e.g., breast, lung prostate, head and neck), structure templates, and treatment plan protocols that use the nomenclature. Each structure requires selection of a label from the Structure Dictionary to identify the structure category. The Structure Dictionary can be updated by the vendor to include the recommended nomenclature. Templates and protocols can be exported as XML files and imported by other users to facilitate adoption of the nomenclature. To automate inspection of structure names for alignment with the recommendations, some users created scripts that can run from Eclipse and highlight structures that are not following recommendations. The availability of writable scripting that would enable the creation of plans and structures adhering to the standard nomenclature was highlighted in an important future advance.

A series of scripts were developed to aid structure naming in the Pinnacle Treatment Planning System. The first script loads a graphical interface that allows user-specified names to auto-populate the Pinnacle region of interest list. This interface shows the master list of TG-263 approved structure names that can be used in Pinnacle. The user can select names from the master list or from a disease site-specific list containing a subset of the master name list. Target and non-standard structures can be added using the TG-263 approved nomenclature.

Once the desired list of structure names is chosen, the names are saved to disk. A secondary Pinnacle script loads the new list of names into the active Pinnacle session and populates the region of interest list. Duplicate names are not inserted.

In addition, each disease site has a script that can simply load all of the TG-263 approved structure names that are deemed commonly used by a radiation oncologist for a given diagnosis. The final script removes all structures from the Pinnacle region of interest list if no contouring was done. This feature provides a quick way to remove unnecessary structures added by the site-specific bulk import.

Similar scripts can be developed for all commercially available treatment planning systems, thus encouraging the wide use of approved structure names in the community. Scripts and templates simplify the steps involved with adopting standard nomenclature and may help overcome some of the barriers to implementation. Staff should be trained using the tools, and leadership will need to affirm a long-term commitment to the standardization effort. Additional training should focus on using the correct nomenclature when the treatment site or organ is outside the department standards. It is noted that the pilot study participants were academically affiliated and may have less opposition to change than smaller clinics with limited staffing. Smaller clinics may, therefore, encounter additional obstacles not
foreseen by this group. Hence, there is even greater importance placed on developing user-friendly scripts which may greatly simplify the adoption of this nomenclature for such clinics.

The pilot study did not require participants to adopt the recommendations for target structures, but did ask that they examine any barriers to adoption of the recommendations. The guidelines had been carefully formulated in conjunction with NRG to facilitate adoption. Several clinics had already converged on the use of relative dose nomenclatures (e.g., PTV_High, PTV_Intermediate or PTV_Mid01, PTV_Low) as part of their routine practice. The relative dose nomenclatures made development of standardized templates possible without requiring conformance to particular dose prescriptions. It also enabled changing prescribed doses during treatment (e.g., move from 68 to 72 Gy) without requiring a change in the associated target structure names (e.g., PTV_High for both vs change from PTV_6800 to PTV_7200). A few clinics had previously standardized the dose units in their planning system on Gy vs cGy. As a result, the shift in dose representation in names (e.g., PTV_5040 vs PTV_50.4Gy) was considered a substantial change and safety concern without a properly educated rollout plan. Switching to relative dose levels (e.g., Low, Intermediate, and High) provided a means to bypass difficulties in changing.

13. Recommendations for Implementation

At the time of publication, over 700 distinct structure names have been published separately on-line in the complete list for this report. In practice, individual clinics only use a small fraction (e.g., 30) of these routinely. The task group recommends use of the standard values for the small subset of structures relevant to their practice or participation in trials. Even a basic effort to change to standardized structure naming is beneficial for the individual clinic, as well as the radiation oncology community as a whole.

The task group recommendations facilitate the ability of clinics to best use their electronic records for safety, productivity, research, and regulatory reporting. The importance of standardizations should be emphasized in training programs for clinical staff.

A range of staff will be affected by clinical implementation of the nomenclature (e.g., physicians, dosimetrist, physicists, therapists, information technology, and administrative personnel). Gradual implementation is encouraged to allow time to develop an understanding of the guidelines, specific string values, and incorporation into their documentation.

A suggested workflow for implementation is listed below:

1. Identify common treatment sites (e.g., prostate, breast, head and neck) and corresponding staffing groups (e.g., physicians, dosimetrist, physicists, therapists) affected by changes in nomenclature.
2. Detail commonalities already in use for those treatment sites for target and non-target structure naming and structure DVH metrics used in treatment plan evaluation.
3. Download the full list of non-target structure names recommended by this report.
4. Save the full list, and make a separate copy for editing.
5. In that Excel sheet, delete rows from the spreadsheet containing structures that are not needed by your clinic. (An example might be: delete all cranial nerve structures, delete all individual heart-vessel structures, etc.)
6. Discuss the final list, guidelines for target and non-target structures, and DVH metrics with the disease site groups and other stakeholders in your clinic as required by your organizational structure.
7. Identify local documentation templates used in the clinical practice that may need to be adjusted along with changes to the nomenclature (e.g., simulation and treatment directives, checklists used in plan review, etc.)

8. Develop a plan for gradual rollout of the nomenclature into clinical practice:
   a. An example might be: implement non-target structure nomenclature and DVH metrics by disease site group over a defined period, and then implement clinic-wide target naming for all disease site groups.
   b. Include all stakeholders in the discussion (e.g., physicians, dosimetry, therapists, physicists).
   c. Consider where there are optimal break points in your clinical process for checking that correct values are used. Examples include plan review, plan check, and quality assurance rounds to review structures and doses.
   d. It may be easier for clinics which are large enough such that practices are broken up by disease site, to implement non-target nomenclatures first on a site-by-site basis and then later implement target nomenclature clinic-wide.

9. Develop a short list and create templates in your treatment planning system containing your new standard structures:
   a. One template that contains all of your standard structures.
   b. Or, individual templates for each treatment type that contain only structures needed for that treatment type.

10. Retain the full list of structures as a reference for adding new structures to your templates as needed in the future.

14. Recommendations for Clinical Trial Study Groups

The ability to automate, exchange, and combine data from multiple groups and studies is important for increasing participation in trials, reducing cost (financial and staff time), and maximizing use of aggregated data over time. The definition of a common nomenclature and guidelines for new structures supports these objectives. Consistent usage of standardized nomenclature among trials is one of the best mechanisms for bringing this consistency to routine practice. We encourage clinical trial groups to adopt these standardizations when defining new studies.

15. Recommendations for Working Group to Succeed Task Group

As technologies and standards advance and data collection becomes more refined, further improvements to the proposed naming schemes may be required. TG-263 recommends that this group transition into a working group which will continue to advance and extend the proposed scheme and maintain an active list of the current nomenclature and guidelines. Standardization to improve communication, data sharing, and safety with focused needs for radiation oncology are important for a wide range of data elements. These include treatment plan names, toxicities, treatment course names, prescription elements, patient-reported outcome items, survival, and recurrence status. Coordination with groups working as part of other organizations is needed to ensure emergence of standards that can be widely applied.

Another important hurdle to adopting one nomenclature in the worldwide RT community is the lack of one global native language. Although the many advantages of using only one language are
widely recognized, unfamiliarity with English or legal reasons may hamper the use of English in many countries. Other obstacles may include character limits and differences in the interpretation of laterality and other abbreviations. A working group could help establish guidelines for the translation of nomenclature and support such activities as needed. Like the task group, the working group should include broad representation of stakeholders, including the DICOM work group and the International Atomic Energy Agency (IAEA), which have experience in working across many languages. The working group might consider creating a translation table from the native language to the English nomenclature which may be (automatically) applied when data needs to be sent, stored, or mined in an international context.

The proposed working group could collaborate with the DICOM work group to construct a dictionary that treats the structure name as a unique ID and provides a meaningful, human-readable description to the user. Using the DICOM standard requires (1) some institutions with recognized authority to create, distribute, and maintain a code scheme, and (2) RT manufacturers that support the use of codes in their segmentation and treatment planning software.

The dictionary could be coupled with an algorithm to derive a human-readable description. Such an approach would allow for controlled growth of the dictionary system. Changes would affect fewer dictionaries, and would allow the ability to create or modify several related structures formed through combinations of the elements in other component dictionaries with the changed elements in the affected dictionary. This allows for more efficient maintenance of the system of component dictionaries. The alternative approach to a single dictionary would involve entering one line of information for all affected combinations of components that are used to build the unique identifiers and the compiled dictionary.

The working group could start maintaining and extending the proposed scheme using the approach of efforts such as FMA, Radlex (Radiology naming scheme), and ICD. These efforts publish their scheme regularly at the aforementioned Bioportal (http://bioportal.bioontology.org/) as a formal ontology and between releases collect community feedback and suggested improvements via tools such as WebProtege (http://protege.stanford.edu/). This could augment and incorporate existing effort to develop radiation oncology specific ontologies such as the Dependency Layered Ontology for Radiation Oncology (http://bioportal.bioontology.org/ontologies/DLORO) and the Radiation Oncology Ontology (http://bioportal.bioontology.org/ontologies/ROO).

This effort is not addressing terms used to define clinical outcomes (e.g., toxicity, local control, survival). The need for establishment and promulgation of a standard nomenclature for structures and DVH metrics with sponsorship by a professional society, such as AAPM, is immediate for many research efforts and for vendor progress on implementation in their systems. Standardization of terms used to define clinical outcomes is important, but not as immediate. These clinical outcome terms should be taken up by the succeeding working group.

16. Summary of Key Take-Home Points

- Standardized nomenclatures add value to radiation oncology by providing a basis for improved communication and the ability to develop automated solutions for data extraction and quality assurance to improve clinical work flows, safety, and research.

- The nomenclature was developed through the combined effort of many clinics, vendors, and clinical trial groups (e.g., NRG, RTOG) to define a viable consensus recommendation. The nomenclature has already been put into routine use in many clinics as part of clinical trials and in vendor software, demonstrating that it is a viable solution.
• The nomenclature was defined to work within the storage and display limits of a range of vended systems to convey information on structure types and laterality.

• Guidelines for target structure naming were created to allow a range of information to be conveyed using a standardized syntax allowing automated parsing of the information from the name.
  ◦ When dose is used as a part of target naming, relative dose levels are recommended (e.g., PTV_High, PTV_Low). If physical dose is required, then units of cGy are preferred, aligning with current recommendations of the ASTRO group defining guidelines for prescriptions and RO-ILS.

• Guidelines for non-target structures and specific values defined for over 700 structures were created, including identification codes for corresponding Foundational Model of Anatomy structures.

• A DVH nomenclature detailing input and output units for high-dose and low-dose metrics and radiobiological metrics was recommended that was designed to use regular expressions to automate parsing parameters needed for automated calculations.

• Non-segmented target structures were recommended for the default standard for contouring. However, target structure nomenclature guidelines define a means to identify segmented structures when they are preferred.

• The nomenclature was piloted in clinic, vendor, and trials groups to prove viability of the recommendations prior to release.

• Vendor participation was important in nomenclature development and is beneficial to facilitate implementation in those vended systems.

17. Acknowledgments

All members of the task group were vital to our ability to identify and vet a practical approach viable for a wide and diverse set of stakeholders. Each person has contributed to our result, and we are grateful to each one. It is not possible in an effort of this size to properly acknowledge the contributions of all members in the ordering of the author list. There are a few people whom we would like to thank explicitly for particular contributions that they carried out beyond the view of most of our members. Susan Richardson provided a spreadsheet from her experience with implementing nomenclatures that formed an important base for the structure nomenclature list that emerged. Peter Gabriel clarified the details of SNOMED CT and FMA improving our understanding of existing ontologies. Elizabeth Covington led a subgroup including Tim Ritter, Tomasz Morgas, and Kathryn Masi that poured over the structure nomenclature list relentlessly, cleaning up typos, removing inconsistencies, and checking FMAIDs. Colleen Fox and Tim Ritter worked tirelessly through the many revisions of the document to collate reviewer comments. We are grateful for the many AAPM, ASTRO, and ESTRO members who have encouraged this work and seen its value to the larger efforts of the radiation oncology community. In particular, we thank Benedick Fraass and Emily Wilson for their support with these professional organizations and Andre Dekker and Coen Hurkmans for their support in the international community and with ESTRO. We would like to thank the many reviewers from AAPM Science Council, AAPM Professional Council, AAPM Therapy Physics Committee, AAPM Quality Assurance and Outcome Improvement Subcommittee, AAPM Working Group on Clinical Trials, ASTRO, ESTRO, and AAMD whose contributions have positively impacted the clarity and depth of the recommendations. We gratefully acknowledge the vision and leadership of Benedick Fraass in coordinating and
coalescing reviews by ASTRO, ESTRO, and AAMD. Special thanks are extended to Walter Bosch and Ying Xiao for the many hours spent working through detailed examinations of the guidelines and structure lists to test, at many stages, implications of the TG’s deliberations on the work of the DICOM working group and NRG. Finally, we thank Robin Stern, Andrea Molineu, Jean Moran, and Saiful Huq for their vision and long hours of support and effort.

18. References


